Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dare Bioscience, Inc.CERU · Entity 7799 | Director | April 03, 2017 | April 05, 2017 |
| INCYTE CORPINCY · Entity 3182 | Director | May 26, 2020 | May 28, 2020 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | January 09, 2026 | January 13, 2026 |
| Prelude Therapeutics IncPRLD · Entity 5561 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dare Bioscience, Inc.
Report date April 03, 2017 · Filed April 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,819 |
Reported balance
After 2017-04-03 transaction · row 1
1 source rowRow 1 · 2017-04-03 · Grant · Acquired 10,273 · Balance 18,819 F1: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the first fiscal quarter of 2017 divided by $0.73, the closing price of the company's common stock on the NASDAQ Global Market on April 3, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the first fiscal quarter of 2017 divided by $0.73, the closing price of the company's common stock on the NASDAQ Global Market on April 3, 2017.
INCYTE CORP
Report date May 26, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 256,813 |
Reported balance
After 2020-05-26 transaction · row 1
1 source rowRow 1 · 2020-05-26 · Grant · Acquired 1,282 · Balance 256,813 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.68 · Expires 2030-05-25 | Direct | 10,514 |
Reported balance
After 2020-05-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-26 · Grant · Acquired 10,514 · Balance 10,514 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). |
| Common StockSEC Table I · non-derivative | IndirectBy Grat | 15,000 |
Reported balance
Holding disclosure · report date 2020-05-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15,000 F2: Shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust (GRAT) on April 3, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust (GRAT) on April 3, 2019.
F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).
MADRIGAL PHARMACEUTICALS, INC.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 187,164 |
Ending reported balance
After 2026-01-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-09 · Exercise / conversion · Acquired 280 · Balance 187,444 Row 2 · 2026-01-09 · Sale · Disposed 280 · Balance 187,164 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.24 to $551.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.80 · Expires 2027-03-02 | Direct | 0 |
Reported balance
After 2026-01-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-09 · Exercise / conversion · Disposed 280 · Balance 0 F4: The shares underlying this stock option are fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectBy SQN LLC | 655,540 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 655,540 F3: The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.24 to $551.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4: The shares underlying this stock option are fully vested and exercisable.
Prelude Therapeutics Inc
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-08 | Direct | 38,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 38,000 · Balance 38,000 F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALEXION PHARMACEUTICALS, INC.
Report date July 21, 2021 · Filed July 23, 2021
Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-21 transaction · row 1
1 source rowRow 1 · 2021-07-21 · Disposition to issuer · Disposed 12,840 · Balance 0 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2024 Filed Jun 28, 2024 01:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 714 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-078748 · ownership.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,449 F1 · shares: Represents a grant of restricted stock units, which vest on June 25, 2025, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:13 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantDirector Stock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001562180-24-005162 · primarydocument.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,270 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0000950170-24-043502 · ownership.xml · derivative · entry 10 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,256 Underlying: Common Stock · 26,270 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 4,866 | $248.59 | $1,209,642.35 |
DisclosureSEC source: 0000950170-24-043502 · ownership.xml · nonDerivative · entry 8 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,735 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.47 to $248.64, inclusive. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,464 | $247.76 | $858,240.99 |
DisclosureSEC source: 0000950170-24-043502 · ownership.xml · nonDerivative · entry 7 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,601 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.47 to $248.24, inclusive. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,028 | $246.96 | $1,241,709.85 |
DisclosureSEC source: 0000950170-24-043502 · ownership.xml · nonDerivative · entry 6 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,065 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.45 to $247.43, inclusive. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,078 | $245.71 | $510,590.78 |
DisclosureSEC source: 0000950170-24-043502 · ownership.xml · nonDerivative · entry 5 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,093 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.43 to $246.28, inclusive. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,663 | $244.86 | $1,386,646.14 |
DisclosureSEC source: 0000950170-24-043502 · ownership.xml · nonDerivative · entry 4 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,171 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.43 to $245.42, inclusive. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,730 | $244.12 | $910,566.48 |
DisclosureSEC source: 0000950170-24-043502 · ownership.xml · nonDerivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,834 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.43 to $244.42, inclusive. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,441 | $242.95 | $350,094.26 |
DisclosureSEC source: 0000950170-24-043502 · ownership.xml · nonDerivative · entry 2 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,564 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.39 to $243.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 26,270 | $9.45 | $248,251.50 |
DisclosureSEC source: 0000950170-24-043502 · ownership.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,613 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · derivative · entry 27 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 232,526 Underlying: Common Stock · 27,613 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F22 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 444 | $245.92 | $109,189.41 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 23 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,735 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.86 to $246.02, inclusive. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,228 | $245.35 | $1,282,668.89 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 22 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,179 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.83 to $245.81, inclusive. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,966 | $244.22 | $968,587.62 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 21 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,407 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.80 to $244.79, inclusive. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 9,264 | $243.20 | $2,253,015.92 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 20 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,373 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.80 to $243.79, inclusive. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,679 | $242.42 | $1,619,097.80 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 19 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,637 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.795 to $242.78, inclusive. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 612 | $241.15 | $147,582.45 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 18 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,316 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.67 to $241.64, inclusive. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,420 | $240.10 | $340,939.02 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 17 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,928 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $239.67 to $240.64, inclusive. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 27,613 | $9.45 | $260,942.85 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 16 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,710 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · derivative · entry 26 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,139 Underlying: Common Stock · 18,710 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F22 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| April 04, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $248.43 | $49,685.00 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 15 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,735 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.41 to $248.44, inclusive. Read SEC document |
| April 04, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 737 | $247.14 | $182,141.07 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 14 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,935 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.80 to $247.54, inclusive. Read SEC document |
| April 04, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,558 | $246.13 | $383,470.85 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 13 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,672 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.70 to $246.65, inclusive. Read SEC document |
| April 04, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,549 | $245.14 | $624,857.02 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 12 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,230 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.65 to $245.61, inclusive. Read SEC document |
| April 04, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 627 | $244.31 | $153,184.75 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 11 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,779 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.65 to $244.63, inclusive. Read SEC document |
| April 04, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,467 | $243.00 | $356,481.73 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 10 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,406 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.60 to $243.55, inclusive. Read SEC document |
| April 04, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,299 | $242.25 | $1,283,678.51 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 9 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,873 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.59 to $242.57, inclusive. Read SEC document |
| April 04, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,273 | $241.07 | $1,512,222.07 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 8 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,172 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.52 to $241.46, inclusive. Read SEC document |
| April 04, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 18,710 | $9.45 | $176,809.50 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 7 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,407 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · derivative · entry 25 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,849 Underlying: Common Stock · 27,407 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F22 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,821 | $246.31 | $448,529.96 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 6 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,735 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.09 to $246.57, inclusive. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 18,806 | $245.34 | $4,613,822.67 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 5 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,556 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.04 to $246.01, inclusive. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 4,301 | $244.58 | $1,051,958.79 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 4 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,362 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.04 to $245.03, inclusive. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,294 | $243.64 | $558,920.94 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,663 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.00 to $243.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 185 | $242.00 | $44,770.00 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 2 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,957 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 27,407 | $9.45 | $258,996.15 |
DisclosureSEC source: 0000899243-24-000265 · doc4.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:14 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantDirector Stock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0001209191-23-038774 · doc4.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2033-06-15 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 16, 2023 Filed Jan 19, 2023 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 26,668 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002095 · doc4.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,668 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date. F1 · balance_after: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 16, 2023 Filed Jan 18, 2024 18:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Tax withholdingCommon Stock | 2,254 | $243.92 | $549,795.68 |
DisclosureSEC source: 0000950170-24-005297 · ownership.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,001 F1 · kind: Represents withholding of shares as payment of the Reporting Person's tax liabilities incident to the vesting of restricted stock units granted to the Reporting Person on January 16, 2023. F2 · balance_after: Represents restricted stock units granted to the Reporting Person on January 16, 2023. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:14 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantDirector Stock Option (Right to Buy) · Derivative | 34,300 | $0.00 Strike: $4.74 | $0.00 |
DisclosureSEC source: 0001562180-22-005298 · primarydocument.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,300 Underlying: Common Stock · 34,300 shares Expires 2032-06-16 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 01:10 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $87.09 | $0.00 |
DisclosureSEC source: 0000899243-22-007766 · doc4.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 16:51 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Disposition to issuerCommon Stock, par value $.0001 per share | 12,840 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000075 · wf-form4_162707345201359.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 21:41 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantDirector Stock Option (Right to Buy) · Derivative | 23,344 | $0.00 Strike: $31.02 | $0.00 |
DisclosureSEC source: 0001209191-21-042474 · doc4.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,344 Underlying: Common Stock · 23,344 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 20, 2021 Filed May 24, 2021 16:34 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 533 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000046 · wf-form4_162188847360889.xml · nonDerivative · entry 2 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,840 F2 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu ofthe annual cash retainer that the director was entitled to receive for service as a director. Read SEC document |
| May 20, 2021 Filed May 24, 2021 16:34 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 1,962 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000046 · wf-form4_162188847360889.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,307 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the first anniversary of the grant date. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 18:35 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $119.49 | $0.00 |
DisclosureSEC source: 0000899243-21-007765 · doc4.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 23:53 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | ConversionSeries B Preferred Stock · Derivative | 152,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052518 · doc4.xml · derivative · entry 5 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 152,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F1 · derivative.exercise_date: The Series A and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F1 · derivative.expiration_date: The Series A and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 23:53 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | ConversionSeries A Preferred Stock · Derivative | 295,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052518 · doc4.xml · derivative · entry 4 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 295,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F1 · derivative.exercise_date: The Series A and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F1 · derivative.expiration_date: The Series A and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 23:53 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | ConversionCommon Stock | 152,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052518 · doc4.xml · nonDerivative · entry 2 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.